# Highlights of This Issue 2275

## SPECIAL FEATURES

### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2277</td>
<td>PRAMEing a Picture of Differentiation Therapy for AML?</td>
<td>Robert L. Redner</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>See article, p. 2562</strong></td>
</tr>
<tr>
<td>2280</td>
<td>Classifying MMR Variants: Time for Revised Nomenclature in Lynch Syndrome</td>
<td>Y. Nancy You and Eduardo Vilar</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>See article, p. 2432</strong></td>
</tr>
</tbody>
</table>

### CCR New Strategies

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2283</td>
<td>New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers</td>
<td>Yuri E. Nikiforov, Linwah Yip, and Marina N. Nikiforova</td>
</tr>
</tbody>
</table>

### CCR Perspectives in Drug Approval

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2289</td>
<td>U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma</td>
<td>Michael Axelson, Ke Liu, Xiaoping Jiang, Kun He, Jian Wang, Hong Zhao, Dubravka Kufirin, Todd Palmbry, Zedong Dong, Anne Marie Russell, Sarah Mikinski, Patricia Keegan, and Richard Pazdur</td>
</tr>
</tbody>
</table>

### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2294</td>
<td>Molecular Pathways: Radiation-Induced Cognitive Impairment</td>
<td>Dana Greene-Schloesser, Elizabeth Moore, and Mike E. Robbins</td>
</tr>
<tr>
<td>2301</td>
<td>Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance</td>
<td>Antonia L. Pritchard and Nicholas K. Hayward</td>
</tr>
</tbody>
</table>

### Review

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2310</td>
<td>Targeting the HGF/e-MET Pathway in Hepatocellular Carcinoma</td>
<td>Lipika Goyal, Mandar D. Muzumdar, and Andrew X. Zhu</td>
</tr>
</tbody>
</table>

## HUMAN CANCER BIOLOGY

### NIK Controls Classical and Alternative NF-κB Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells

Lina Odqvist, Margarita Sánchez-Beato, Santiago Montes-Moreno, Esperanza Martín-Sánchez, Raquel Pajares, Lydia Sánchez-Verde, Pablo L. Ortiz-Romo, Jose Rodriguez, Socorro M. Rodríguez-Pinilla, Francisca Iniesta-Martínez, Juan Carlos Solera-Arroyo, Rafael Ramos-Asensio, Teresa Flores, Javier Menarguez Palanca, Federico García Bragado, Purificación Domínguez Franjo, and Miguel A. Piris

### High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition

Elisabeth Wik, Even Birkeland, Jone Trovik, Henrica MJ. Werner, Erling A. Holvik, Siv Mjøs, Camilla Krakstad, Kanthida Kusonmanno, Karen Maauland, Ingunn M. Stefansson, Frederik Holst, Kjell Petersen, Anne M. Oyan, Ronald Simon, Karl H. Kalland, William Ricketts, Lars A. Akslen, and Helga B. Salvesen

### PI3K/AKT Signaling Is Essential for Communication between Tissue-Infiltrating Mast Cells, Macrophages, and Epithelial Cells in Colitis-Induced Cancer

Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia

Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
Christina A. von Roemeling, Laura A. Marlow, Johnny J. Wei, Simon J. Cooper, Thomas R. Caulfield, Kevin Wu, Winston W. Tan, Han W. Tun, and John A. Copland

Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells

The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells

Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
Suzanne E. Wardell, Erik R. Nelson, Christina A. Chao, and Donald P. McDonnell

Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Inga Hinrichsen, Angela Brieger, Jörg Trojan, Stefan Zeuzem, Mel NILbert, and Guido Plotz

Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study
Daniel W. Lin, Lisa F. Newcomb, Elissa C. Brown, James D. Brooks, Peter R. Carroll, Ziding Feng, Martin E. Gleave, Raymond S. Lance, Martin G. Sanda, Ian M. Thompson, John T. Wei, and Peter S. Nelson, for the Canary Prostate Active Surveillance Study Investigators

PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma
Hironobu Shigaki, Yoshifumi Baba, Masayuki Watanabe, Asuka Murata, Takakazu Ishimoto, Masaaki Iwatsuki, Shiro Iwagami, Katsuhiko Nosho, and Hideo Baba

Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
Qi Zhao, Otavia L. Caballero, Ian D. Davis, Eric Jonasch, Pheroze Tamboli, W.K. Alfred Yung, John N. Weinstein, Kenna Shaw for the TCGA research network, Robert L. Strausberg, and Jun Yao

Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors
Antonella Chiuchi, Chiara Novello, Giovanna Magagnoli, Emanuel F. Petricoin III, Jianhong Deng, Maria S. Benassi, Piero Picci, Iosif Vaisman, Virginia Espina, and Lance A. Liotta

Improved Survival with HPV among African Americans with Oropharyngeal Cancer
Maria J. Worsham, Josena K. Stephen, Kang Mei Chen, Meredith Mahan, Vanessa Schweitzer, Shaleta Havard, and George Divine
Sequential Binary Gene Ratio Tests Define a Novel Molecular Diagnostic Strategy for Malignant Pleural Mesothelioma
Assunta De Rienzo, William G. Richards, Beow Y. Yeap, Melissa H. Coleman, Peter E. Sugarbaker, Lucian R. Chirieac, Yaoyu E. Wang, John Quackenbush, Roderick V. Jensen, and Raphael Bueno

Tissue Redox Activity as a Hallmark of Carcinogenesis: From Early to Terminal Stages of Cancer
Rumiana Bakalova, Zhivko Zhelev, Ichio Aoki, and Tsuneo Saga

Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
Thomas S.C. Ng, David Wert, Hargun Sohi, Daniel Procissi, David Colcher, Andrew A. Rauthitschek, and Russell E. Jacobs

Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study
Jong-Lyel Roh, Xin Victoria Wang, Judith Manola, David Sidransky, Arlene A. Forastiere, and Wayne M. Koch

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaprakash D. Karkera, Reyna Favis, Dana Gafney, Alice Shapiro, Panteli Theocharous, Yusri A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Joanna Romejko-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie-Lee Esseltine, George Mulligan, and Deborah Ricci

FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
Liang Xie, Xinying Su, Lin Zhang, Xiaolu Yin, Lili Tang, Xiuhua Zhang, Yanping Xu, Zeren Gao, Kunji Liu, Minhua Zhou, Beirong Gao, Danping Shen, Lianhai Zhang, Jiafu Ji, Paul R. Gavine, Jingchuan Zhang, Elaine Kilgour, Xiaolin Zhang, and Qunsheng Ji

Characteristics of Lung Cancers Harboring NRAS Mutations
Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Christine M. Lovly, Xi Chen, Charles M. Rudin, Teresa Moran, David Ross Camidge, Cindy L. Vnencak-Jones, Lynne Berry, Yumei Pan, Hidelumi Sasaki, Jeffrey A. Engelman, Edward B. Baron, Steven M. Dubinett, Wilbur A. Franklin, Gregory J. Riely, Martin L. Sos, Mark G. Kris, Dora Dias-Santagata, Marc Ladanyi, Paul A. Bunn Jr, and William Pao
ABOUT THE COVER

Assembling of microRNA-loaded transferrin-conjugated-nanoparticles to target acute myeloid leukemia (AML) blasts. The nanoparticle core was composed of negatively charged microRNA molecules (miR, \( \text{miR} \)) and positively charged polyethylenimine (PEI, \( \text{PEI} \)). Empty nanoparticles were composed of DOPE (\( \text{DOPE} \)), linoleic acid (\( \text{Linoleic Acid} \)), and DMG-PEG (\( \text{DMG-PEG} \)). After the loading of the PEI-miR core in the nanoparticles, transferrin-PEG-DSPE (\( \text{Transferrin-PEG-DSPE} \)) was inserted into the nanoparticle surface for specific targeting of leukemia blasts. The background depicts a cytospin of AML blasts derived from a mouse with AML treated with miR-loaded nanoparticles. For details, see the article by Huang and colleagues on page 2355 of this issue.

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org
Clinical Cancer Research

19 (9)


Updated version  Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/9

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.